MX369768B - Composición farmacéutica de coenzima q10 para usarse en un método para tratar cáncer. - Google Patents
Composición farmacéutica de coenzima q10 para usarse en un método para tratar cáncer.Info
- Publication number
- MX369768B MX369768B MX2014014492A MX2014014492A MX369768B MX 369768 B MX369768 B MX 369768B MX 2014014492 A MX2014014492 A MX 2014014492A MX 2014014492 A MX2014014492 A MX 2014014492A MX 369768 B MX369768 B MX 369768B
- Authority
- MX
- Mexico
- Prior art keywords
- coenzyme
- treatment
- solid tumors
- subject
- coq1o
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261654245P | 2012-06-01 | 2012-06-01 | |
| PCT/US2013/043785 WO2013181639A1 (en) | 2012-06-01 | 2013-05-31 | Treatment of solid tumors using coenzyme q10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014014492A MX2014014492A (es) | 2015-05-12 |
| MX369768B true MX369768B (es) | 2019-11-21 |
Family
ID=49673946
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014014492A MX369768B (es) | 2012-06-01 | 2013-05-31 | Composición farmacéutica de coenzima q10 para usarse en un método para tratar cáncer. |
| MX2019013776A MX2019013776A (es) | 2012-06-01 | 2014-11-27 | Tratamiento de tumores solidos utilizando coenzima q10. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019013776A MX2019013776A (es) | 2012-06-01 | 2014-11-27 | Tratamiento de tumores solidos utilizando coenzima q10. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20140017317A1 (enExample) |
| EP (1) | EP2854528B8 (enExample) |
| JP (3) | JP6352905B2 (enExample) |
| KR (2) | KR102163948B1 (enExample) |
| CN (1) | CN104507308A (enExample) |
| AU (2) | AU2013267166A1 (enExample) |
| BR (1) | BR112014029954A2 (enExample) |
| CA (2) | CA3090268A1 (enExample) |
| EA (1) | EA032345B1 (enExample) |
| ES (1) | ES2761449T3 (enExample) |
| IL (1) | IL236008B (enExample) |
| IN (1) | IN2014DN10734A (enExample) |
| MX (2) | MX369768B (enExample) |
| NZ (1) | NZ702369A (enExample) |
| SG (1) | SG11201407880QA (enExample) |
| WO (1) | WO2013181639A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010247750B2 (en) | 2009-05-11 | 2016-09-22 | Berg Llc | Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| KR101933732B1 (ko) | 2011-04-04 | 2018-12-28 | 버그 엘엘씨 | 중추 신경 시스템 종양들의 치료 방법 |
| IN2014DN10734A (enExample) * | 2012-06-01 | 2015-09-04 | Berg Llc | |
| SG11201508272YA (en) * | 2013-04-08 | 2015-11-27 | Berg Llc | Treatment of cancer using coenzyme q10 combination therapies |
| HUE050060T2 (hu) | 2013-09-04 | 2020-11-30 | Berg Llc | Eljárások rák kezelésére koenzim Q10 folyamatos infúziójával |
| US9996463B2 (en) * | 2015-11-10 | 2018-06-12 | International Business Machines Corporation | Selection and placement of volumes in a storage system using stripes |
| WO2017087576A1 (en) * | 2015-11-16 | 2017-05-26 | Berg Llc | Methods of treatment of temozolomide-resistant glioma using coenzyme q10 |
| US20170255565A1 (en) * | 2016-03-02 | 2017-09-07 | Intel Corporation | Method and apparatus for providing a contiguously addressable memory region by remapping an address space |
| US20200093751A1 (en) * | 2016-06-28 | 2020-03-26 | Der-Yang Tien | Chemoprotective/chemoactive nanodroplets and methods of use thereof |
| MA52274A (fr) * | 2017-05-17 | 2021-02-24 | Berg Llc | Utilisation de formulations de coenzyme q10 dans le traitement et la prévention de l'épidermolyse bulleuse |
| CA3239264A1 (en) * | 2021-12-01 | 2023-06-08 | Gambro Lundia Ab | New dialysis fluid |
| WO2025087731A1 (en) * | 2023-10-24 | 2025-05-01 | Gambro Lundia Ab | Compositions comprising insulin and ketones bodies to treat cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US20070104688A1 (en) | 2003-02-13 | 2007-05-10 | City Of Hope | Small interfering RNA mediated transcriptional gene silencing in mammalian cells |
| WO2005048925A2 (en) * | 2003-11-14 | 2005-06-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds |
| KR101395370B1 (ko) | 2004-01-22 | 2014-05-14 | 유니버시티 오브 마이애미 | 국소용 코-엔자임 큐10 제형 및 그의 사용 방법 |
| JPWO2008069276A1 (ja) * | 2006-12-06 | 2010-03-25 | 株式会社カネカ | 癌治療剤および発癌抑制剤 |
| AU2008228764B2 (en) | 2007-03-22 | 2014-05-08 | Berg Llc | Topical formulations having enhanced bioavailability |
| EP2217227B1 (en) * | 2007-11-12 | 2013-08-21 | BiPar Sciences, Inc. | Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
| US20090247608A1 (en) | 2007-12-04 | 2009-10-01 | Alnylam Pharmaceuticals, Inc. | Targeting Lipids |
| US8247435B2 (en) * | 2009-02-19 | 2012-08-21 | Thornthwaite Jerry T | Formulations for treating human and animal diseases |
| AU2010247750B2 (en) | 2009-05-11 | 2016-09-22 | Berg Llc | Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| GB0913193D0 (en) | 2009-07-29 | 2009-09-02 | Johnson Matthey Plc | Deoxygenation process |
| KR102008658B1 (ko) | 2010-03-12 | 2019-08-08 | 베르그 엘엘씨 | 코엔자임 Ｑ10(ＣｏＱ10)의 정맥내 제형 및 이의 사용 방법 |
| JP5932993B2 (ja) | 2011-06-17 | 2016-06-08 | バーグ エルエルシー | 吸入可能な医薬組成物 |
| IN2014DN10734A (enExample) * | 2012-06-01 | 2015-09-04 | Berg Llc |
-
2013
- 2013-05-31 IN IN10734DEN2014 patent/IN2014DN10734A/en unknown
- 2013-05-31 SG SG11201407880QA patent/SG11201407880QA/en unknown
- 2013-05-31 AU AU2013267166A patent/AU2013267166A1/en not_active Abandoned
- 2013-05-31 ES ES13797642T patent/ES2761449T3/es active Active
- 2013-05-31 KR KR1020147037100A patent/KR102163948B1/ko active Active
- 2013-05-31 CA CA3090268A patent/CA3090268A1/en not_active Abandoned
- 2013-05-31 EA EA201492187A patent/EA032345B1/ru not_active IP Right Cessation
- 2013-05-31 MX MX2014014492A patent/MX369768B/es active IP Right Grant
- 2013-05-31 WO PCT/US2013/043785 patent/WO2013181639A1/en not_active Ceased
- 2013-05-31 CA CA2875150A patent/CA2875150C/en active Active
- 2013-05-31 BR BR112014029954A patent/BR112014029954A2/pt not_active IP Right Cessation
- 2013-05-31 CN CN201380040105.3A patent/CN104507308A/zh active Pending
- 2013-05-31 NZ NZ702369A patent/NZ702369A/en not_active IP Right Cessation
- 2013-05-31 KR KR1020207028370A patent/KR20200118233A/ko not_active Ceased
- 2013-05-31 JP JP2015515272A patent/JP6352905B2/ja active Active
- 2013-05-31 EP EP13797642.9A patent/EP2854528B8/en active Active
- 2013-05-31 US US13/907,726 patent/US20140017317A1/en not_active Abandoned
-
2014
- 2014-11-27 MX MX2019013776A patent/MX2019013776A/es unknown
- 2014-11-30 IL IL236008A patent/IL236008B/en active IP Right Grant
-
2016
- 2016-10-10 US US15/289,770 patent/US20170216223A1/en not_active Abandoned
-
2017
- 2017-04-19 AU AU2017202567A patent/AU2017202567B2/en not_active Ceased
-
2018
- 2018-06-07 JP JP2018109093A patent/JP2018168164A/ja not_active Withdrawn
-
2020
- 2020-07-29 JP JP2020127877A patent/JP7225167B2/ja active Active
-
2021
- 2021-05-17 US US17/321,699 patent/US20220096399A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019013776A (es) | Tratamiento de tumores solidos utilizando coenzima q10. | |
| MX2019014986A (es) | Formulaciones de coenzima q10 y metodos de uso. | |
| WO2014018563A3 (en) | Methods for the treatment of cancer | |
| EP3046622A4 (en) | Positron emission tomography guided proton therapy | |
| AU2012240222A8 (en) | Methods of treating central nervous system tumors | |
| IL246544B (en) | A compound for the treatment of patients with ros1 mutant cancer cells | |
| PT3456717T (pt) | Derivado de 4,6-diamino-quinolina-3-carbonitrilo como modulador do cancro da tiróide de osaka (cot) para o tratamento de doenças inflamatórias | |
| WO2014116833A3 (en) | Compositions and methods for detecting neoplasia | |
| EP3456339A3 (en) | Novel immunotherapy against several tumors, such as lung cancer including nsclc | |
| EP4276200A3 (en) | Fgfr-tacc fusion proteins and methods thereof | |
| WO2014039533A3 (en) | Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin | |
| PT3394063T (pt) | Ligandos macrocíclicos com (um) grupo(s) picolinato, os seus complexos, bem como as suas utilizações médicas | |
| PH12015501854A1 (en) | Factor ix polypeptide formulations | |
| MX379622B (es) | Compuestos espirociclicos | |
| PH12016501751A1 (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| MX2017014436A (es) | Compuestos biciclicos. | |
| EP2982752A4 (en) | Glucuronyl transferase, gene encoding same, and use thereof | |
| EA201301265A1 (ru) | Способ лечения солидных злокачественных опухолей, включая прогрессирующие или метастатические солидные злокачественные опухоли | |
| MX2016015568A (es) | Derivados de nucleosidos para el tratamiento del cancer. | |
| EP3089745A4 (en) | Compounds, compositions, and methods for the treatment of cancers | |
| EP4541423A3 (en) | Dosing regimen of avelumab for the treatment of cancer | |
| JO3630B1 (ar) | توليفة أليسيرتيب وباكليتاكسيل لعلاج السرطان | |
| EP2836217A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE ADMINISTRATION OF ANTICANCER CHEMOTHERAPEUTIC AGENTS | |
| MX351961B (es) | Analogos de diazonamida. | |
| 朱松亚 | Photo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |